FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

02 Mar, 2021

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
Photo by Startaê Team on Unsplash

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.

Biotechnology Health Care North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: